Blog

AAFA Meets With DOT to Advocate for Equal Rights for People With Asthma and Allergies on Planes

The Asthma and Allergy Foundation of America (AAFA) met with the Office of the General Counsel of the U.S. Department of Transportation (DOT). We spoke with members of their Office of Aviation Enforcement and Proceedings and Consumer Protection Division on behalf of people with asthma and allergies. We shared how critical it is that people with asthma and allergies who have to be on planes with emotional support animals have equal rights.

Be Part of a Project to Shape New Eczema Treatments

AAFA has joined with four other nonprofit organizations that serve people with eczema to launch “More Than Skin Deep.” This project will inform and shape the development of treatments for eczema. A main part the project is a patient-focused drug development (PFDD) meeting on Sept. 23, 2019, in Washington, D.C.

Dupixent® Shows Positive Results in Phase 3 of Trial for Ages 6 to 11 With Severe Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.

Managing Asthma in St. Louis: It's Scary Not to Be Able to Breathe

Growing up, Jerica Gordon’s sister had asthma, but she does not remember her having any asthma attacks. “So when my son was having trouble breathing, I thought it was just congestion or something. There was no wheezing that I remember hearing,” she shared. In November 2016, Jerica took her son Jonathan Robinson, Jr., then age 5, to the emergency room.

Protect Yourself From Dust Mites With Asthma and Allergy Friendly Pillows and Pillow Covers

When you lay your head on your pillow at night, all you want to think about is comfort – not millions of dust mites. And if you have a dust mite allergy, having all those microscopic insects near your head can make you uncomfortable by triggering allergy and asthma symptoms. You can create a healthier sleeping environment by using pillows that are CERTIFIED asthma & allergy friendly®. Or you can cover your existing pillow in a CERTIFIED pillow cover.

New Digital Long-Term Control Inhaler Works With Smartphones to Help People Track Inhaler Use

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma.

Asthma and Allergy Foundation of America Responds to Premature ICER Review of New Peanut Allergy Treatments

The Asthma and Allergy Foundation of America (AAFA) addresses concerns regarding the Final Evidence Report assessing the clinical effectiveness and value of treatments for peanut allergy released by the Institute for Clinical and Economic Review (ICER) on July 10, 2019. ICER’s report may cause concern for the allergy community that the findings will restrict access to new treatments for peanut allergy.

FDA Approves Dupixent® for Chronic Rhinosinusitis With Nasal Polyps

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.

Post
×
×
×
×